This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
by Zacks Equity Research
TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.
TGTXPositive Net Change ARGXNegative Net Change LQDANegative Net Change IMCRPositive Net Change
biotechs
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results
by Zacks Equity Research
SNY halts its phase III MOBILIZE study after an interim review finds riliprubart unlikely to deliver sufficient efficacy in refractory CIDP patients.
SNYPositive Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs medical pharmaceuticals
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
by Kinjel Shah
MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.
PFEPositive Net Change NVONegative Net Change LLYNegative Net Change AMGNPositive Net Change
biotechs
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
by Zacks Equity Research
argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment to adult patients regardless of antibody status.
ARGXNegative Net Change LQDANegative Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
by Zacks Equity Research
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
GSKPositive Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
by Zacks Equity Research
Incyte will acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039 and expanding its hematology growth prospects.
NVSNegative Net Change INCYPositive Net Change LQDANegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
by Zacks Equity Research
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
RVMDPositive Net Change ERASPositive Net Change TNGXPositive Net Change
biotechs medical pharmaceuticals
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
by Zacks Equity Research
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
GSKPositive Net Change RPRXNegative Net Change NUVLNegative Net Change
biotechs medical pharmaceuticals
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?
by Ahan Chakraborty
LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.
NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
by Zacks Equity Research
SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.
SNYPositive Net Change BMYPositive Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals